TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. Advise pregnant women and females of reproductive potential of the potential risk to a fetus.

Discover the latest advancements in breast cancer treatment at the 24th Annual International Congress, featuring expert ...

Trodelvy (sacituzumab govitecan-hziy) is a prescription infusion that treats certain forms of breast cancer in adults. Learn about dosage, side effects, and more.

Trodelvy, in combination with Merck's immunotherapy Keytruda, lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to new results.

Trodelvy (sacituzumab govitecan-hziy) is a brand-name IV infusion prescribed for certain types of breast cancer in adults. As with other drugs, Trodelvy can cause side effects, such as diarrhea ...

Trodelvy is a first-in-class Trop-2-directed antibody-drug conjugate. The ASCENT-03 study is a global, open-label, randomized phase III trial evaluating the efficacy and safety of Trodelvy ...

Trodelvy plus Keytruda improved progression-free survival in PD-L1–positive, advanced TNBC, reducing disease progression or death risk by 35% compared to chemotherapy plus Keytruda. The phase 3 ASCENT ...

These findings support the expectation that Trodelvy combined with Keytruda will become the new SOC in PD-L1-positive TNBC, shifting the frontline treatment paradigm from chemoimmunotherapy to ADC ...

(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...

Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer ...

Trodelvy when given in combination with Keytruda resulted in a median progression-free survival (PFS) of 11.2 months. FOSTER CITY, Calif., May 31, 2025--Gilead Sciences, Inc. ...